Nutritional and Metabolic Diseases

All Conditions

Gland and Hormone Related Diseases

Diseases and Abnormalities at or Before Birth

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Nervous System Diseases

Heart and Blood Diseases

Symptoms and General Pathology

Metabolic Diseases

Diabetes Mellitus

Congenital Abnormalities

Pregnancy Complications

Cerebrovascular Disorders

Endocrine System Diseases

Neurologic Manifestations

Urogenital Diseases

Female Urogenital Diseases

Female Urogenital Diseases and Pregnancy Complications

Brain Diseases

Central Nervous System Diseases

Vascular Diseases

Dietary intake converted into dietary pattern scores.

Dietary intake

Walter C. Willett, MD, DrPH

To study, prospectively, the association between dietary patterns and risk of health outcomes (cardiovascular, metabolic, endocrine, neurological, skeletal muscular, cancer) in cohort study of 116,671 women age 24 to 44 years at baseline in 1989 (the Nurses' Health Study II; NHS II).

Health status and lifestyle information was self-reported on a questionnaire at baseline, and on questionnaires distributed to participants biennially thereafter. Dietary intake data was collected in form of a comprehensive, 131-item food frequency questionnaire (FFQ), distributed among participants every four years. The response rate remained over 90%. Dietary data was validated using biomarkers, health status data using medical records.

Dietary pattern scores were derived from FFQs using cumulative average whenever possible from years preceding the outcomes.

Multivariable Cox proportional hazards models were used to evaluate associations between dietary pattern scores and health outcomes, except in case of pregnancy complications (such as gestational diabetes mellitus/GDM and hypertensive disorders of pregnancy/HDPs) where multivariable logistic regression models with generalized estimating equations, with an exchangeable working correlation structure to account for correlated outcomes between pregnancies.

Our analysis was based on a cohort of female registered nurses.

Dietary Patterns and Health Outcomes (Cardiovascular, Metabolic, Endocrine, Neurological, Skeletal Muscular, Cancer)

Necrosis of heart muscle secondary to prolonged ischemia.

Sudden death of brain cells due to lack of oxygen

Glucose intolerance with onset/first recognition during pregnancy

Pregnancy induced hypertension, toxemia/preeclampsia

Fragility fractures of common sites such as hip and wrist.

Physical function such as falls, walking, and self care

National Institutes of Health (NIH)

National Cancer Institute (NCI)

National Institute of Environmental Health Sciences (NIEHS)

Harvard School of Public Health (HSPH)

NHS II Principal Investigator; Professor of Epidemiology and Nutrition

Neoplasms

Substance Related Disorders

Pain, Postoperative

Urinary Bladder Neoplasms

Postoperative Complications

Pain

Drug-Related Side Effects and Adverse Reactions

Chemically-Induced Disorders

Analgesics

All Drugs and Chemicals

Central Nervous System Depressants

Antitussive Agents

Respiratory System Agents

Anti-Obesity Agents

Vasoconstrictor Agents

Morphine

Methadone

Analgesics, Opioid

Narcotics

Phenylpropanolamine

Guaifenesin

Chlorpheniramine, phenylpropanolamine drug combination

A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.

A 10 ml syringe with 2 mg/ml of morphine will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.

One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.

One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.

The role of a single-dose intraoperative methadone on postoperative pain and opioid consumption in patients undergoing Surgeon Accuracy Robot Assistant cystectomy. A prospective double-blind, randomized controlled trial investigating the effect of a single-dose of intraoperative methadone in patients undergoing robotassisted cystectomy.

During early recovery after surgery, intravenous opioids are typically administered to control the pain, either as intermittent bolus administration by nursing staff or by a patient-controlled analgesia device. Unfortunately, repeated doses or boluses of shorter-acting opioids, such as morphine, oxycodone and fentanyl, result in fluctuating blood concentrations, with the inherent risk of only relatively brief periods of adequate pain relief. Moreover, the use of shorter-acting opioids increases the risk of opioid-associated side effects, such as sedation, nausea and vomiting. An alternative approach to the postoperative use of shorter-acting opioids is therefore called for.

In this respect, methadone is an opioid with unique pharmalogical properties that may be advantageous when applied intraoperatively. A single-dose of this long acting opioid could provide a stable analgesia and potentially reduce the need for shorter-acting opioids

Method:

110 patients will be included in an investigator-initiated, prospective, randomised, double-blind, controlled trial with two arms: intervention arm (methadone 0.15 mg/kg ideal body weight). Control arm (morphine 0.15 mg/kg ideal body weight). The study will be GCP-monitored, and is approved by the Danish Health and Medicines Authority (2020041652) and the Central Denmark Region Committees on Health Research Ethics (1-10-72-275-19).

Hypothesis We hypothesize that a single-dose of intravenous intraoperative methadone is efficient and safe for the treatment of postoperative pain after cystectomy.

Objectives The primary objective is to determine whether a single-dose of intravenous methadone reduces postoperative opioid consumption when compared to morphine. The secondary objectives are to compare the effect and safety of intravenous methadone and morphine on postoperative pain, side effects, patient satisfaction and length of stay.

Randomization and medication will be handled by hospital pharmacy. Randomisation list will be concealed until all statistical analyses are made.

* plan for data analysis was decided upon at a meeting with a statistician on September 7th, 2023. The plan was made before A and B lists were obtained from the hospital pharmacy. This study will be undertaken as an equivalence trial with the application of intention to treat analysis. Missing data are assumed to be missing at random. Primary outcome will be analyzed paired or unpaired t-test for difference, depending on distribution. Analysis of secondary outcome NRS will be reported as median(interquartile range) and compared between groups at the various times using the Mann-Whitney U test. If normal distributed multilevel mixed effects linear regression will be carried out. Analysis of other secondary outcomes will be dichotomized and presented for 3 and 24 hours with X2 test.

Methadone in Cystectomy Patients

Clinical Effectiveness and Safety of Intraoperative Methadone in Patients

• Pain intensity (NRS, 0-10) at rest and coughing, questionnaires answered by nurse.

• Nausea and/or vomiting (PONV) on a 4-point Likert scale (none/mild/moderate/severe). Questionnaires answered by nurse.

Gastrointestinal function (flatus, stools) and laxatives ordained.

• Opioid consumption within the first 3 hours after extubation

• Opioid consumption within the first 24 hours after extubation

NRS (0-10) at rest and when coughing. Questionnaires answered by nurse.

• Opioid consumption within the first 72 hours after extubation

Level of sedation (Ramsey Sedation Score) assessed by PACU nurse.

Patient satisfaction with pain management (NRS 0-10) Questionnaires answered by nurse.

• Time from arrival to discharge from PACU and hospital (hours and minutes)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dietary Patterns and Health Outcomes (Cardiovascular, Metabolic, Endocrine, Neurological, Skeletal Muscular, Cancer)	NCT03328546	Cardiovascular ... Cerebrovascular... Metabolic Disea... Neoplasms Endocrine Syste... Neurologic Symp... Skeletal Anomal... Diabetes Mellit... Pregnancy Compl...	Dietary intake	24 Years - 44 Years	Harvard School of Public Health (HSPH)
Methadone in Cystectomy Patients	NCT04475029	Pain, Postopera... Postoperative C... Pathologic Proc... Bladder Cancer Pain Signs and Sympt... Neurologic Mani... Neurologic Symp... Side Effect of ...	Methadone Morphine	18 Years - 110 Years	University of Aarhus
Methadone in Cystectomy Patients	NCT04475029	Pain, Postopera... Postoperative C... Pathologic Proc... Bladder Cancer Pain Signs and Sympt... Neurologic Mani... Neurologic Symp... Side Effect of ...	Methadone Morphine	18 Years - 110 Years	University of Aarhus

Spots Global Cancer Trial Database for neurologic symptoms